Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.ijid.2021.02.056

http://scihub22266oqcxt.onion/10.1016/j.ijid.2021.02.056
suck pdf from google scholar
33607304!7885681!33607304
unlimited free pdf from europmc33607304    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33607304      Int+J+Infect+Dis 2021 ; 105 (ä): 274-276
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • The role of ibrutinib in COVID-19 hyperinflammation: A case report #MMPMID33607304
  • Maynard S; Ros-Soto J; Chaidos A; Innes A; Paleja K; Mirvis E; Buti N; Sharp H; Palanicawandar R; Milojkovic D
  • Int J Infect Dis 2021[Apr]; 105 (ä): 274-276 PMID33607304show ga
  • Immune modulation in COVID-19 is emerging as an important therapeutic strategy as increasing evidence suggests that inflammatory pathways are implicated in lung damage. Bruton tyrosine kinase inhibitors (BTKi), such as ibrutinib, are commonly used to treat indolent B-cell neoplasms and chronic graft-versus-host disease (GvHD). Given their potential to suppress pulmonary inflammatory cytokines and lessen acute lung injury, this could be applicable in the context of hospitalised COVID-19 patients. We describe an 81 year-old male receiving ibrutinib for Waldenstrom macroglobulinaemia (WM) who was hospitalised with COVID-19. On stopping the BTKi due to concerns of additional immunosuppression, he required non-invasive ventilation (NIV) in the intensive care unit (ICU) and demonstrated prompt clinical recovery when ibrutinib was reinstated. Continuing ibrutinib in patients with COVID-19 may be advantageous given its immunomodulatory properties and withdrawal of ibrutinib therapy may be detrimental. Further evidence is required to explore the potential therapeutic impact of BTKis and other immunomodulatory agents on the clinical course of COVID-19 as is currently being carried out in a number of clinical trials.
  • |*COVID-19 Drug Treatment[MESH]
  • |Adenine/*analogs & derivatives/therapeutic use[MESH]
  • |Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors[MESH]
  • |Aged, 80 and over[MESH]
  • |COVID-19/*immunology[MESH]
  • |Humans[MESH]
  • |Immunomodulation[MESH]
  • |Male[MESH]
  • |Piperidines/*therapeutic use[MESH]
  • |Protein Kinase Inhibitors/*therapeutic use[MESH]
  • |SARS-CoV-2/immunology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box